Discovery of potent, selective chymase inhibitors via fragment linking strategies.

Chymase plays an important and diverse role in the homeostasis of a number of cardiovascular processes. Herein, we describe the identification of potent, selective chymase inhibitors, developed using fragment-based, structure-guided linking and optimization techniques. High-concentration biophysical screening methods followed by high-throughput crystallography identified an oxindole fragment bound to the S1 pocket of the protein exhibiting a novel interaction pattern hitherto not observed in chymase inhibitors. X-ray crystallographic structures were used to guide the elaboration/linking of the fragment, ultimately leading to a potent inhibitor that was >100-fold selective over cathepsin G and that mitigated a number of liabilities associated with poor physicochemical properties of the series it was derived from.

[1]  I. Bot,et al.  Mast cells in atherosclerosis , 2011, Thrombosis and Haemostasis.

[2]  C. Pemberton,et al.  Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. , 2009, Cardiovascular research.

[3]  K. Amin The role of mast cells in allergic inflammation. , 2012, Respiratory medicine.

[4]  P. Veeraveedu,et al.  Chymase Inhibition Reduces the Progression to Heart Failure After Autoimmune Myocarditis in Rats , 2007, Experimental biology and medicine.

[5]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[6]  L. Groome,et al.  Chymotrypsin-Like Protease (Chymase) Mediates Endothelial Activation by Factors Derived From Preeclamptic Placentas , 2009, Reproductive Sciences.

[7]  A. Hopkins,et al.  Emerging role of surface plasmon resonance in fragment-based drug discovery. , 2011, Future medicinal chemistry.

[8]  S. Takai,et al.  Chymase Plays an Important Role in Left Ventricular Remodeling Induced by Intermittent Hypoxia in Mice , 2009, Hypertension.

[9]  G. Caughey Mast cell proteases as protective and inflammatory mediators. , 2011, Advances in experimental medicine and biology.

[10]  G. Siegal,et al.  Target Immobilization as a Strategy for NMR-Based Fragment Screening , 2010, Journal of biomolecular screening.

[11]  M. Tuck,et al.  Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors , 2000, Current hypertension reports.

[12]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[13]  Robert Abel,et al.  Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding , 2007, Proceedings of the National Academy of Sciences.

[14]  J. S. Janicki,et al.  Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. , 2006, Cardiovascular research.

[15]  S. Takai,et al.  Targets of chymase inhibitors , 2011, Expert opinion on therapeutic targets.

[16]  E. Oliveira,et al.  Alternative pathways for angiotensin II generation in the cardiovascular system. , 2011, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[17]  S. Takai,et al.  Chymase Inhibition Prevents Cardiac Fibrosis and Dysfunction after Myocardial Infarction in Rats , 2006, Hypertension Research.

[18]  Paul D. Leeson,et al.  The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.

[19]  N. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.

[20]  S. Takai,et al.  Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. , 1996, Life sciences.

[21]  S. Takai,et al.  Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[22]  S. Doggrell,et al.  Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. , 2005, Canadian journal of physiology and pharmacology.

[23]  S. Takai,et al.  Multiple mechanisms for the action of chymase inhibitors. , 2012, Journal of pharmacological sciences.

[24]  M. Arooj,et al.  3D QSAR Pharmacophore Modeling, in Silico Screening, and Density Functional Theory (DFT) Approaches for Identification of Human Chymase Inhibitors , 2011, International journal of molecular sciences.

[25]  S. Takai,et al.  Chymase-dependent angiotensin II formation in human vascular tissue. , 1999, Circulation.

[26]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[27]  Gerald T Miwa,et al.  Bioactivation of drugs: risk and drug design. , 2011, Annual review of pharmacology and toxicology.

[28]  Nirmal Singh,et al.  Mast cells: an expanding pathophysiological role from allergy to other disorders , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

[29]  S. Savvides,et al.  Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. , 2007, Journal of medicinal chemistry.

[30]  J. Sadoshima,et al.  Knocking Out Angiotensin II in the Heart , 2011, Current hypertension reports.

[31]  Daniel R. Albaugh,et al.  Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region. , 2011, Bioorganic & medicinal chemistry letters.

[32]  P. Cummins A new addition to the renin-angiotensin peptide family: proAngiotensin-12 (PA12). , 2009, Cardiovascular research.

[33]  T. Denney,et al.  Chymase Inhibition Prevents Fibronectin and Myofibrillar Loss and Improves Cardiomyocyte Function and LV Torsion Angle in Dogs With Isolated Mitral Regurgitation , 2010, Circulation.

[34]  K. Okoń,et al.  Mast cells and cancer: enemies or allies? , 2012, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[35]  Narayanasami Sukumar,et al.  A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase , 2005, Journal of Biological Chemistry.

[36]  S. Takai,et al.  New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. , 2010, Journal of pharmacological sciences.

[37]  F. Sellke,et al.  Chymase Inhibition Reduces Infarction and Matrix Metalloproteinase-9 Activation and Attenuates Inflammation and Fibrosis after Acute Myocardial Ischemia/Reperfusion , 2011, Journal of Pharmacology and Experimental Therapeutics.

[38]  Allen B Reitz,et al.  Hit triage using efficiency indices after screening of compound libraries in drug discovery. , 2009, Current topics in medicinal chemistry.